Clinical Trial

A Study of HDM2020 in Patients With Advanced Sq-NSCLC

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to learn if the study drug can treat in advanced squamous non-small cell lung cancer(NSCLC) patients. The main questions it aims to answer are: Is the drug safe and tolerable? Does the drug show antitumor activity? Participants will receive the study drug once(D1) or twice(D1.D8) every three weeks, and undergo imaging-based efficacy assessments every six weeks.
Trial Details
NCT Number NCT07638891
Lead Sponsor Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Conditions Squamous Non-small Cell Lung Cancer(NSCLC)
Enrollment 150 participants
Start Date 2026-04-01
Primary Completion 2027-01-31 (estimated)
Study Completion 2027-11-03 (estimated)
Updated on ClinicalTrials.gov 2026-06-10